By Robert B. Livingston, Stephen K. Carter (auth.)
The scientific trials application of anti-tumor medicinal drugs was once all started via the nationwide melanoma Institute in 1955. long ago 15 years, this nationwide community has accrued a wide physique of information on the entire famous anti-tumor medicines in addition to upon new, experimentally promising brokers. whereas crucial of those reviews were released, there has remained a wealth of knowledge now not quite often on hand to the medical neighborhood. Drs. Carter and Livingston haven't in basic terms succeeded in organ~z~ng this huge corpus, they've got furthermore analyzed and interpreted the scientific information in a manner that would be hugely invaluable for future years. From a perusal of this quantity it turns into obvious that a few medicines are extra energetic opposed to definite tumors than were discovered; that the facts for the task of sure medications opposed to particular tumors is usually tenuous; unusually, that a few hugely lively brokers have by no means been attempted opposed to a number of the quite universal tumors. Their huge paintings has supplied not just entry to the not easy information, it has additionally proven the necessity for examine to fill in vital gaps in our wisdom. The authors and the IFI/Plenum Press are to be congratulated for this beneficial and demanding paintings. C. Gordon Zubrod, M. D. medical Director for Chemotherapy nationwide melanoma Institute nationwide Institutes of wellbeing and fitness Bethesda, Maryland v Acknowledgment The authors desire to thank Dr. C. Gordon Zubrod and Dr.
Read Online or Download Single Agents in Cancer Chemotherapy PDF
Similar oncology books
Regardless of way of life advancements, the occurrence of rectal melanoma is expanding in industrialised international locations. fast advances in expertise, turning out to be wisdom of the organic historical past of the sickness and nearer realization to sufferers' caliber of lifestyles after surgical procedure have resulted in a much less invasive technique. within the final 15 years, the surgical method has shifted from prolonged resection to sphincter-saving tactics, that includes a multidiscipinary technique and a excessive point of specialisation.
The preeminent ebook on melanoma cytogenetics—now in a precious new editionLike its profitable predecessors, melanoma Cytogenetics, 3rd version keeps to supply authoritative insurance of neoplastic procedures on the chromosomal point of genomic association. Now up to date and multiplied, this new version comprises special info at the most up-to-date advances within the box, incorporating an unlimited volume of recent cytogenetic in addition to molecular genetic information from the newest easy and scientific investigations.
The reason for utilizing intraoperative irradiation (IORT) is predicated at the awareness that tolerable doses of everlasting beam radiation are usually inadequate to accomplish keep watch over of in the community complicated malignancies. In those situations, the IORT component to therapy turns into the optimum conformal means of irradiation, on account that dose-limiting organs or constructions can both be surgically displaced or safe via placement of lead protecting.
The medical trials application of anti-tumor medicines was once began via the nationwide melanoma Institute in 1955. some time past 15 years, this nationwide community has accumulated a wide physique of knowledge on the entire famous anti-tumor medicines in addition to upon new, experimentally promising brokers. whereas crucial of those reviews were released, there has remained a wealth of knowledge now not often on hand to the medical neighborhood.
Extra resources for Single Agents in Cancer Chemotherapy
Repeat ~ 4 wks later. 1 CR. 4 mg/kg x 1, IV (HN ) - unmaintained. Children. 1 CR, 4 PR, witt median duration 54 days. HN 2-+O CR, 1 PR of 11, with duration 51 days. 2 mg/kg/day, PO as tolerated. vinblastine-+l CR, 5 PR of 17. 30-40 mg/kg x 1, IV; then (after 2-6 wks for marrow recovery), 3 mg/kg/day, PO. 1 mg/kg q 7-14 days, for 3 mo (HN 2 ). All PRo HN 2-+2 CR, 6 PR of 14. 5 mg/kg/day x 6, then 6-20 (usually 10) mg/kg/wk or q 2 wks, IV; (2) 45-100 mg/kg x 1, IV, then 75-100% of initial dose as soon as peripheral blood count began to rise (usually 19-23 days), and again as tolerated.
2) 30 mg/kg x 1, IV, then 10-15 mg/kg q 1-2 wks after WBC recovery to ~ 4000. 3 mo. WCCG study. Total. 5 mg/kg/day x 6, IV, then 6-20 mg/kg (usually 10 mg/kg)/wk or q 2 wks. (2) 45-100 mg/kg x 1, IV, then 75 to 100% of initial dose "as soon as peripheral blood count began to show a rebound from its lowest point", usually in 19-23 days, and again as tolerated. o 1 8 Varied. PR; ECOG study. 3 mg/kg/day, IV or PO, x 5-35 days. (Majority received total dose in 5 days). Phase I study. PRo 1 gm/day x 7, IV or PO.
0 CR. Children. ) -l'- " m C ~ » ::J: "lJ oCI> ::J: "lJ 5 ~ () 56 49 2 122 24 7 10 2 219 49 78 79 4 5 51. 5 73 17 33 % Response 72 /I Pts Responding /I Pts Evaluated Ref II Total, intermittent induction schedules. Total. CR in 28/93 evaluated = 30%. CR in 9/60 evaluated in American studies = 15%. · Uracil mustard (UM) +1/6, HN2 +1/6 responses. MST = 5 mo for CTX-, 5 mo for UM-, and 3 mo for HN2-treated patients. 5 gm/m x 1, IV; repeated q 3 wks as tolerated. 1 CR. 4 mg/kg x 1, IV (HN 2 ) , then daily PO maintenance (chlorambucil).